Coverage complications are not unusual in the U.S. healthcare system. But the challenge is magnified for these obesity ...
Wave goodbye to the Part D "donut hole" and hello to a $2,000 cap on the amount you'll pay for medications. But other changes ...
It’s time to treat obesity as a chronic disease and have Medicare cover these life-changing AOMs. By taking action now, we ...
Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent ...
Opinion: It’s time we prioritize innovation and invest in solutions that truly address the root cause of this chronic and ...
Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...
Many employers and insurers are scaling back coverage and Medicare doesn’t cover the drugs for obesity. Meantime, some big ...
These findings support the claim that Medicare Advantage (MA) payments may be driven more by diagnosis and coding practices ...
Supplies of high-demand obesity drugs are improving – but they’re not easier to get - ‘There are a lot of people right now ...
This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.
and obesity) and health factors (cholesterol, blood pressure, glucose control, and metabolic syndrome) that contribute to cardiovascular health. The AHA Heart Disease and Stroke Statistical Update ...